科研动态PubMed 摘要

来那卡帕韦在HIV-1感染治疗与预防中的应用:临床疗效及耐药选择风险的叙述性综述。

PubMed 白名单日捞 · 2026-11-09

完整摘要 · 中文译文

来那卡帕韦(Lenacapavir)是首创的HIV-1衣壳抑制剂。通过作用于结构蛋白而非病毒酶,它抑制复制周期的多个阶段,且与现有药物类别无交叉耐药性;皮下给药后半衰期为8-12周,允许每六个月给药一次方案。本研究进行了叙述性综述,检索PubMed和ClinicalTrials.gov至2026年7月,并参考2期和3期试验、结构与建模研究及监管文件。在计划方案转换的病毒学抑制成人中,比克替拉韦/来那卡帕韦(ARTISTRY-1和ARTISTRY-2)及每周口服伊斯拉曲韦/来那卡帕韦(ISLEND-1和ISLEND-2)的第48周治疗差异范围为-1.0至0.3个百分点,各95%置信区间上限均低于预设的非劣效界值4个百分点。这些是研究性转换方案:来那卡帕韦本身目前仅获批用于多重耐药HIV-1感染和暴露前预防,而比克替拉韦/来那卡帕韦和伊斯拉曲韦/来那卡帕韦联合方案均尚未获批。在多重耐药感染中,CAPELLA试验中85%的参与者在第156周时HIV-1 RNA < 50 copies/mL(排除缺失数据时)。在预防方面,PURPOSE 1中来那卡帕韦组2,134名参与者中无感染发生(0.00/100人年;相对背景的发病率比:0.00,95% CI:0.00-0.04),而恩曲他滨-替诺福韦艾拉酚胺组的发病率并无差异 与背景发生率相比(发生率比:0.84,95% CI:0.55-1.28)。使来那卡帕韦具有强效的药代动力学特性被认为同时是其最主要的脆弱性。作为一种药理学担忧,亚治疗浓度尾段可造成功能性单药治疗状态,此时当病毒在能抑制野生型但不能抑制耐药变异的浓度下复制时(突变选择窗),可能筛选出耐药。模型预测在末次注射后106-235天出现新生耐药,并且对于N74D和双突变体,选择窗甚至与每六个月给药方案的稳态浓度重叠,因此这些突变体不仅可能在停药后尾段被筛选出,而且可能在按计划继续给药期间被筛选出。临床研究中实际观察到的耐药有限且有条件:N74D出现在PURPOSE 2来那卡帕韦组感染的两名参与者中,尽管预期药物浓度存在;而在CAPELLA中,每一名出现耐药的参与者其背景方案均无活性或服用不充分,表明该脆弱性是可管理的。因此,来那卡帕韦需要仔细的患者选择、完全有活性的伴随药物以及有计划停药策略。

完整摘要 · 英文原文

Lenacapavir is a first-in-class HIV-1 capsid inhibitor. By acting on a structural protein rather than a viral enzyme, it inhibits several stages of the replication cycle and shows no cross-resistance with the available drug classes; a half-life of 8-12 weeks after subcutaneous administration allows a six-monthly regimen. A narrative review was conducted, searching PubMed and ClinicalTrials.gov up to July 2026 and drawing on phase 2 and phase 3 trials, structural and modelling studies, and regulatory documents. In virologically suppressed adults undergoing a planned regimen switch, the week-48 treatment differences for bictegravir/lenacapavir (ARTISTRY-1 and ARTISTRY-2) and for weekly oral islatravir/lenacapavir (ISLEND-1 and ISLEND-2) ranged from -1.0 to 0.3 percentage points, with the upper bound of each 95% confidence interval lying below the prespecified non-inferiority margin of 4 percentage points. These are investigational switch regimens: lenacapavir itself is currently approved only for multidrug-resistant HIV-1 infection and for pre-exposure prophylaxis, whereas neither the bictegravir/lenacapavir nor the islatravir/lenacapavir combination has yet been authorised. In multidrug-resistant infection, 85% of participants in CAPELLA had HIV-1 RNA < 50 copies/mL at week 156 when missing data were excluded. In prevention, no infection occurred among the 2,134 participants in the lenacapavir arm of PURPOSE 1 (0.00/100 person-years; incidence rate ratio vs background: 0.00, 95% CI: 0.00-0.04), whereas the incidence in the emtricitabine-tenofovir alafenamide arm did not differ from the background incidence (incidence rate ratio: 0.84, 95% CI: 0.55-1.28). The pharmacokinetic property that gives lenacapavir its strength is argued to be, at the same time, its principal vulnerability. As a pharmacological concern, the subtherapeutic concentration tail can create a state of functional monotherapy in which resistance may be selected when the virus replicates at concentrations that suppress the wild-type but not a resistant variant (the mutant selection window). Modelling predicts de novo resistance 106-235 days after the last injection and, for N74D and the double mutants, a selection window overlapping even the steady-state concentrations of the six-monthly regimen, so that these mutants may be selected not only during the post-discontinuation tail but also while dosing continues as planned. Resistance actually observed in clinical studies has been limited and conditional: N74D arose in the two participants infected in the lenacapavir arm of PURPOSE 2 despite expected drug concentrations, and in CAPELLA every participant who developed resistance had a background regimen that was inactive or inadequately taken, indicating that the vulnerability is manageable. Lenacapavir therefore requires careful patient selection, fully active companion drugs, and a planned discontinuation strategy.

English
Lenacapavir in the Treatment and Prevention of HIV-1 Infection: A Narrative Review of Clinical Efficacy and Resistance Selection Risk.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界